Title: | A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101) |
Authors: | Takashina, Taichi Browse this author |
Asahina, Hajime Browse this author |
Oizumi, Satoshi Browse this author →KAKEN DB |
Yamada, Noriyuki Browse this author |
Harada, Masao Browse this author |
Takamura, Kei Browse this author |
Yokouchi, Hiroshi Browse this author |
Harada, Toshiyuki Browse this author |
Honjo, Osamu Browse this author |
Ogi, Takahiro Browse this author |
Morikawa, Naoto Browse this author |
Kinoshita, Ichiro Browse this author →KAKEN DB |
Honda, Ryoichi Browse this author |
Nakano, Kosuke Browse this author |
Kanazawa, Kenya Browse this author |
Amano, Toraji Browse this author |
Dosaka-Akita, Hirotoshi Browse this author →KAKEN DB |
Isobe, Hiroshi Browse this author →KAKEN DB |
Nishimura, Masaharu Browse this author →KAKEN DB |
Keywords: | Maintenance therapy |
Pemetrexed |
Bevacizumab |
Erlotinib |
Non-small cell lung cancer |
Issue Date: | Dec-2018 |
Publisher: | Springer |
Journal Title: | International journal of clinical oncology |
Volume: | 23 |
Issue: | 6 |
Start Page: | 1060 |
End Page: | 1069 |
Publisher DOI: | 10.1007/s10147-018-1318-z |
PMID: | 30027464 |
Abstract: | Background: This study evaluated the efficacy and safety of switch maintenance erlotinib and bevacizumab after induction therapy with carboplatin/pemetrexed/bevacizumab for non-squamous non-small cell lung cancer (NSCLC) with wild-type EGFR. Methods: Enrolled patients had treatment-naive, advanced non-squamous NSCLC with wild-type EGFR. Carboplatin [area under the curve (AUC) 5.0], pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) were administered on day 1 every 3 weeks for 4-6 cycles. Maintenance therapy with erlotinib (150 mg/body) on day 1 through 21 plus bevacizumab on day 1 every 3 weeks was continued until disease progression or unacceptable toxicity. The primary endpoint was 6-month progression-free survival (PFS); secondary endpoints included overall survival (OS), overall response rate (ORR), toxicity, and quality of life (QOL). Results: Fifty-one patients were enrolled between September 2011 and June 2014. The median number of cycles for induction and maintenance therapy was 4 (range 1-6) and 4 (range 1-20). Twenty-nine patients (58%) received maintenance therapy. The 6-month PFS rate was 59.5% [95% confidence interval (CI) 45.0-72.6%]. The ORR was 48.0% (95% CI 34.8-61.5%), and disease control rate was 86.0% (95% CI 73.8-93.0%). The median PFS and OS were 6.5 months (95% CI 5.8-7.2 months) and 21.4 months (95% CI 15.9-26.9 months), respectively. Although grades ≥ 3 adverse events were observed in 33 patients (66.0%), most were hematologic; there was no febrile neutropenia. QOL was maintained throughout treatment. Conclusions: Carboplatin/pemetrexed/bevacizumab followed by erlotinib and bevacizumab maintenance showed modest efficacy and was well tolerated in non-squamous NSCLC patients with wild-type EGFR. |
Rights: | This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10147-018-1318-z |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/74964 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|